Last reviewed 2026-04-20 · How we verify

Defekton (CARPIPRAMINE)

Phase 2 active Small molecule

Defekton (generic name: CARPIPRAMINE) is a carpipramine drug. It is currently in Phase 2 development.

Defekton works by blocking dopamine receptors in the brain, which can help regulate mood and behavior.

Defekton, also known as carpipramine, is a small molecule drug that targets the D(2) dopamine receptor. It is classified as a carpipramine, but its commercial status and approved indications are unknown. The mechanism of action involves blocking dopamine receptors in the brain, which can help alleviate symptoms of certain psychiatric conditions. However, more information is needed to fully understand its clinical use and safety profile. Further research is required to determine its efficacy and potential side effects.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CARPIPRAMINE
Drug class	carpipramine
Target	D(2) dopamine receptor, D(3) dopamine receptor
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your brain is like a radio station with many different channels. Dopamine is like a signal that helps different parts of the brain communicate with each other. By blocking dopamine receptors, Defekton can help reduce the volume of this signal, which can help calm down overactive brain activity and alleviate symptoms of certain psychiatric conditions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Defekton CI brief — competitive landscape report
Defekton updates RSS · CI watch RSS

Frequently asked questions about Defekton

What is Defekton?

Defekton (CARPIPRAMINE) is a carpipramine drug.

How does Defekton work?

Defekton works by blocking dopamine receptors in the brain, which can help regulate mood and behavior.

What is the generic name of Defekton?

CARPIPRAMINE is the generic (nonproprietary) name of Defekton.

What drug class is Defekton in?

Defekton belongs to the carpipramine class. See all carpipramine drugs at /class/carpipramine.

What development phase is Defekton in?

Defekton is in Phase 2.

What does Defekton target?

Defekton targets D(2) dopamine receptor, D(3) dopamine receptor and is a carpipramine.

Drug class: All carpipramine drugs
Target: All drugs targeting D(2) dopamine receptor, D(3) dopamine receptor
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing